| Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412 PS Römer, S Berr, E Avota, SY Na, M Battaglia, I ten Berge, H Einsele, ... Blood, The Journal of the American Society of Hematology 118 (26), 6772-6782, 2011 | 198 | 2011 |
| Human regulatory T cells are selectively activated by low‐dose application of the CD28 superagonist TGN1412/TAB08 P Tabares, S Berr, PS Römer, S Chuvpilo, AA Matskevich, D Tyrsin, ... European journal of immunology 44 (4), 1225-1236, 2014 | 120 | 2014 |
| Cell contact–dependent priming and Fc interaction with CD32+ immune cells contribute to the TGN1412-triggered cytokine response P Bartholomaeus, LY Semmler, T Bukur, V Boisguerin, PS Roemer, ... The Journal of Immunology 192 (5), 2091-2098, 2014 | 64 | 2014 |
| From TGN1412 to TAB08: the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis D Tyrsin, S Chuvpilo, A Matskevich, D Nemenov, PS Römer, P Tabares, ... Clinical and experimental rheumatology 34 (4 Suppl 98), 45-48, 2016 | 50 | 2016 |
| Antibody dose and corticosteroid sensitivity separate TGN1412 induced inflammatory cytokine release from activation of regulatory T-cells PTWS Berr, PS Römer, SCWA Matckevich, DTWY Fedotov, HEWHP Tony, ... | | |
John C. CastleChief Data Scientist, Monte Rosa TherapeuticsVerified email at monterosatx.com
